Positive results have been reported from a trial of siRNA—small interfering RNA—therapy targeting coagulation factor XI (FXI) in patients with chronic coronary artery disease. The randomised, double-blind, placebo-controlled European Phase 2a study assessing vortosiran (Ribocure Pharmaceuticals) involved patients with chronic coronary artery disease with previous myocardial infarction (MI) receiving aspirin. Presenting the results at the […] The post Trial of siRNA therapy in coronary artery disease reports positive initial results appeared first on Cardiovascular News .